Cargando…
Ziv-aflibercept in metastatic colorectal cancer
The combination of cytotoxic chemotherapy and antiangiogenic agents has become a conventional treatment option for patients with metastatic colorectal cancer. Ziv-aflibercept is a fusion protein which acts as a decoy receptor for vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental gro...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3869833/ https://www.ncbi.nlm.nih.gov/pubmed/24368879 http://dx.doi.org/10.2147/BTT.S39360 |
_version_ | 1782296623354740736 |
---|---|
author | Patel, Anuj Sun, Weijing |
author_facet | Patel, Anuj Sun, Weijing |
author_sort | Patel, Anuj |
collection | PubMed |
description | The combination of cytotoxic chemotherapy and antiangiogenic agents has become a conventional treatment option for patients with metastatic colorectal cancer. Ziv-aflibercept is a fusion protein which acts as a decoy receptor for vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental growth factor (PlGF); it was approved in combination with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) for the treatment of patients with metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing fluoropyrimidine-based regimen. Herein we review the role of tumor angiogenesis as the rationale for antiangiogenic therapy, the clinical data associated with ziv-aflibercept, and its current role as a treatment option compared to other antiangiogenic agents, such as bevacizumab and regorafenib. |
format | Online Article Text |
id | pubmed-3869833 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-38698332013-12-24 Ziv-aflibercept in metastatic colorectal cancer Patel, Anuj Sun, Weijing Biologics Review The combination of cytotoxic chemotherapy and antiangiogenic agents has become a conventional treatment option for patients with metastatic colorectal cancer. Ziv-aflibercept is a fusion protein which acts as a decoy receptor for vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental growth factor (PlGF); it was approved in combination with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) for the treatment of patients with metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing fluoropyrimidine-based regimen. Herein we review the role of tumor angiogenesis as the rationale for antiangiogenic therapy, the clinical data associated with ziv-aflibercept, and its current role as a treatment option compared to other antiangiogenic agents, such as bevacizumab and regorafenib. Dove Medical Press 2013-12-16 /pmc/articles/PMC3869833/ /pubmed/24368879 http://dx.doi.org/10.2147/BTT.S39360 Text en © 2014 Patel and Sun. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Patel, Anuj Sun, Weijing Ziv-aflibercept in metastatic colorectal cancer |
title | Ziv-aflibercept in metastatic colorectal cancer |
title_full | Ziv-aflibercept in metastatic colorectal cancer |
title_fullStr | Ziv-aflibercept in metastatic colorectal cancer |
title_full_unstemmed | Ziv-aflibercept in metastatic colorectal cancer |
title_short | Ziv-aflibercept in metastatic colorectal cancer |
title_sort | ziv-aflibercept in metastatic colorectal cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3869833/ https://www.ncbi.nlm.nih.gov/pubmed/24368879 http://dx.doi.org/10.2147/BTT.S39360 |
work_keys_str_mv | AT patelanuj zivafliberceptinmetastaticcolorectalcancer AT sunweijing zivafliberceptinmetastaticcolorectalcancer |